Drug Trial Radar · NCT00512135
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
Last checked: Nov 20, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
801
Actual
Start
Jun 18, 2007
Primary completion
Dec 28, 2009
Study completion Dec 28, 2009
Sponsor
- Lead sponsor
- Merz Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.
Conditions
- Glabellar Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 units)Drug
Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Baseline up to Month 30
- Incidence of Adverse Events of Special Interest (AESI)Time frame: Baseline up to Month 30
- Percentage of Responders at Maximum Frown as Assessed by the Investigator According to Facial Wrinkle Scale (FWS)Time frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
- Percentage of Responders at Rest as Assessed by the Investigator According to FWSTime frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
- Percentage of Responders at Maximum Frown by Participant's Assessment on the 4-point ScaleTime frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
- Percentage of Responders at Rest by Participant's Assessment on the 4-point ScaleTime frame: At evaluation visit (30 days after injection) and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
- Degree of Glabellar Lines as Assessed by the Participant on the 6-point Likert Type Scale at Maximum FrownTime frame: At evaluation visit (30 days after injection); and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
- Degree of Glabellar Lines as Assessed by the Participant on the 6-point Likert Type Scale at RestTime frame: At evaluation visit (30 days after injection); and at last control visit (85 days after last injection) in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
- Time to Onset of Treatment EffectTime frame: From injection visit up to date of onset of treatment effect in each treatment cycle from Cycle 1 to Cycle 8 (each cycle length >=85 days)
Locations
25 sites in 3 countries. Site status is shown where the registry gives one.
Skin Care Centre
Los Angeles, California
About Skin Dermatology
Englewood, Colorado
Centre for Cosmetic Enhancement
Aventura, Florida
Brandt
Coral Gables, Florida
Advanced Dermatology Research Institute
Lincolnshire, Illinois
Laser &Skin Surgery Center of Indiana
Carmel, Indiana
Coleman
Metairie, Louisiana
Skin Care Physisians of Chestnut Hill
Chestnut Hill, Massachusetts
Schlessinger
Omaha, Nebraska
Image Dermatology P.C.
Montclair, New Jersey
Narins
White Plains, New York
Flynn Consulting PLLC
Raleigh, North Carolina
Tennessee Clinical Research Center
Nashville, Tennessee
Carruthers Dermatology Centre Inc.
Vancouver, British Columbia, Canada
Solish
Toronto, Ontario, Canada
Charité Berlin - Klinik für Dermatologie
Berlin, Germany
Rosenparkklinik
Darmstadt, Germany
Krankenhaus Dresden Friedrichstadt
Dresden, Germany
Johann-Wolfgang-Goethe- Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Universität Hamburg
Hamburg, Germany
SCIderm GmbH
Hamburg, Germany
Uniklinik Saarland
Homburg / Saar, Germany
Dr. Michael Sebastian
Mahlow, Germany
Dr. Hans-Ulrich Voigt
München, Germany
Dr. Thomas Dirschka
Wuppertal, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.